Tepezza Marketing, Sales Practices, and Products Liability Litigation
The causation theory linking Tepezza (Teprotumumab) to hearing loss involves the inhibition of IGF-1 signaling in the cochlea, which is essential for hair cell maintenance and survival. Disruption of this pathway may lead to hair cell damage or death, resulting in sensorineural hearing loss. Clinical studies and FDA reports support this mechanism, with evidence indicating that the adverse effects are likely related to the drug's impact on cochlear hair cells, supported by post-marketing surveillance and scientific literature.
277
Pending actions
287
Total actions filed
Active
Status
06/02/2023
Established
Who qualifies
Plaintiffs must have used Tepezza after its FDA approval in January 2020, experienced permanent hearing loss or tinnitus, and their injuries must be supported by medical records and adverse event reports. The injuries should have occurred following exposure to Tepezza during its approved use period. Exact dosage thresholds are not specified, but the exposure must be during the post-approval period, with claims supported by clinical and adverse event data. Plaintiffs are expected to file claims within a procedural window implied by court schedules, though specific deadlines are not publicly detailed.
Products involved
- Tepezza (brand name)
- Teprotumumab (generic name)
Alleged injuries
- permanent hearing loss
- tinnitus
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
